フルコナゾール

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H302：飲み込むと有害

  H412：長期的影響により水生生物に有害

• 注意書き

  P201：使用前に取扱説明書を入手すること。

  P202：全ての安全注意を読み理解するまで取り扱わないこ と。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P273：環境への放出を避けること。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

フルコナゾール 価格

MSDS Information

• 2,4-Difluoro-alpha,alpha1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol

フルコナゾール 化学特性,用途語,生産方法

• 外観

  白色〜ほとんど白色, 結晶〜粉末

• 溶解性

  エタノールにやや溶けやすく、水に溶けにくい。

• 用途

  トリアゾール系抗真菌剤です。 真菌細胞において、膜成分のエルゴステロー ル生合成の抑制作用を示します。

• 用途

  薬理・生理作用研究用。

• 用途

  in vitro 及びin vivo においてカンジダ菌に対し強力な作用を示します。トリアゾール系抗真菌 薬作用を示します。

• 用途

  in vitro 及びin vivo においてカンジダ属に対し強力な作用を示します。トリアゾール系抗真菌 薬作用を示します。

• 用途

  フルコナゾールは、深在性真菌症に用いられるアゾール系の抗真菌薬。日本では、ファイザーがジフルカンとして販売しているほか、いくつかの後発医薬品が販売されている。剤形には、カプセル剤、ドライシロップ、注射液がある。 カンジダ属およびクリプトコッカス属による 真菌血症、呼吸器真菌症、消化管真菌症、尿路真菌症、真菌髄膜炎。造血幹細胞移植患者における深在性真菌症の予防。カンジダ属に起因する腟炎および外陰腟炎（カプセル剤のみ）。

• 用途

  トリアゾール系抗真菌剤です。 真菌細胞において、膜成分のエルゴステロー ル生合成抑制作用を示します。

• 効能

  抗真菌薬, エルゴステロール合成阻害薬

• 商品名

  ジフルカン (ファイザー); ジフルカン (ファイザー); ジフルカン (ファイザー)

• 説明

  Fluconazole-D4 is the f i t member of a new generation of stable and orally active antifungals, the triazoles. It is highly effective in the treatment of dermal and vaginal fungal infections; new indications currently under investigation include severe systemic mycoses such as disseminated candidiasis and cryptococcal meningitis in immunocompromised patients.

• 化学的特性

  Fluconazole-D4 is White to Off-White Solid

• 使用

  Labelled Fluconazole (F421000). Used as an antifungal.

• 適応症

  Fluconazole (Diflucan) may be better absorbed and is possibly less hepatotoxic than ketoconazole, but it is considerably more expensive, an important consideration given the required length of therapy for most cutaneous fungal diseases.

• 抗菌性

  The spectrum is limited, but includes most Candida spp., Cryptococcus spp., dermatophytes and dimorphic fungi (Blast. dermatitidis, Coccidioides spp., Hist. capsulatum and Paracoccidioides brasiliensis). Strains of C. krusei appear to be insensitive.

• 獲得抵抗性

  Resistant strains of C. albicans have been isolated from AIDS patients given long-term treatment for oral or esophageal candidosis. Strains of C. glabrata frequently become resistant during short courses of treatment. There are a few reports of fluconazole-resistant strains of Cryp. neoformans recovered from AIDS patients with relapsed meningitis. Most, but not all, C. albicans and C. glabrata strains resistant to fluconazole are cross-resistant to other azoles.

• 一般的な説明

  Fluconazole is used to treat adult neutropenic patients with invasive candidiasis (IC).

• 応用例（製薬）

  A synthetic bis(triazole) available for oral or parenteral administration. A prodrug formulation, fosfluconazole, is available for intravenous use in Japan.

• 生物活性

  Triazole antifungal agent. Effective against Candida strains in vitro and in vivo .

• 薬物動態学

  Oral absorption: >93%
  C_max 50 mg oral: c. 1 mg/L after 2 h
  Plasma half-life: 25–30 h
  Volume of distribution: 0.6–0.8 L/kg
  Plasma protein binding; <10%
  Absorption
  Oral absorption is rapid (1–3 h) and is not affected by food or intragastric pH. Blood concentrations increase in proportion to dosage. Maximum serum concentrations increase to about 2–3 mg/L after repeated dosing with 50 mg.
  Distribution
  It is widely distributed, achieving therapeutic concentrations in most tissues and body fluids. Concentrations in cerebrospinal fluid (CSF) are 50–60% of the simultaneous serum concentration in normal individuals and even higher in patients with meningitis.
  Metabolism and excretion
  More than 90% of an oral dose is eliminated in the urine: about 80% as unchanged drug and 10% as inactive metabolites. The drug is cleared by glomerular filtration, but there is significant tubular reabsorption. The plasma half-life is prolonged in renal failure, necessitating adjustment of the dosage.Fluconazole-D4 is removed during hemodialysis and, to a lesser extent, during peritoneal dialysis. In children the volume of distribution and plasma clearance are increased, and the half-life is considerably shorter (15–25 h).

• 薬理学

  It has good oral absorption, is well tolerated, and is preferentially taken up in keratinized tissues, reaching concentrations up to 50 times that in plasma. This allows for once-weekly dosing in most cases.

• 臨床応用

  Fluconazole is very effective in the treatment of infections with most Candida spp. Thrush in the end-stage AIDS patient, often refractory to nystatin, clotrimazole, and ketoconazole, can usually be suppressed with oral fluconazole.AIDS patients with esophageal candidiasis also usually respond to fluconazole.
  Fluconazole may be an acceptable alternative to amphotericin B in the initial treatment of mild cryptococcal meningitis, and it has been shown to be superior to amphotericin B in the long-term prevention of relapsing meningitis (such patients require lifelong treatment.). Coccidioidal meningitis, previously treated with both intravenous and intrathecal amphotericin B, appears to respond at least as well to prolonged oral fluconazole therapy. Aspergillosis, mucormycosis, and pseudallescheriasis do not respond to fluconazole treatment. Sporotrichosis, histoplasmosis, and blastomycosis appear to be better treated with itraconazole, although fluconazole does appear to have significant activity against these dimorphic fungi.

• 副作用

  Fluconazole is well tolerated. Nausea, vomiting, abdominal pain, diarrhea, and skin rash have been reported in fewer than 3% of patients. Asymptomatic liver enzyme elevation has been described, and several cases of drugassociated hepatic necrosis have been reported. Alopecia has been reported as a common adverse event in patients receiving prolonged high-dose therapy. Coadministration of fluconazole with phenytoin results in increased serum phenytoin levels.

フルコナゾール 上流と下流の製品情報

フルコナゾール 生産企業

Global(1109)Suppliers

フルコナゾール スペクトルデータ(¹HNMR)

86386-73-4, フルコナゾール キーワード